Core Viewpoint - In May 2025, over 70% of the 8,451 comparable mixed funds experienced net value increases, indicating a positive trend in the market [1] Fund Performance Summary - A total of 54 mixed funds achieved a monthly increase of over 10%, with Jinxin Value Selected Mixed A and C leading at 19.38% and 19.36% respectively [2] - Jinxin Value Selected Mixed A and C, established on September 1, 2017, reported year-to-date returns of 32.65% and 32.60%, and cumulative returns of 48.85% and 49.57% as of May 30, 2025 [2] - The top ten holdings of Jinxin Value Selected Mixed A and C focus on the pharmaceutical and biotechnology sectors, particularly in innovative industries [2] - Huabao Pharmaceutical and Biological Mixed A achieved a monthly increase of 11.49%, with a year-to-date return of 41.55% and a cumulative return of 381.22% since its inception [3] Fund Decline Summary - 15 mixed funds saw declines exceeding 10% in May, with Furong Fuxin Mixed C and A at the bottom with -12.39% and -12.38% respectively [4] - Furong Fuxin Mixed C and A focus on humanoid robotics, with their top holdings including Huachen Equipment and Qinchuan Machine Tool [4] Fund Manager Insights - The current fund manager for Jinxin Value Selected Mixed A and C is Zhao Haoran, who has a background in financial research and joined Jinxin Fund in August 2022 [2] - Huabao Pharmaceutical and Biological Mixed A is managed by Zhang Jintao, who has extensive experience in investment research across various financial institutions [3] - Furong Fuxin Mixed C and A are co-managed by Li Yanzheng and Mao Yunhong, both of whom have significant experience in research and fund management [4]